Ontada

WATCH: In this HealthTree Foundation interview, Ontada's Lisa Herms, PhD, discusses a research study examining real-world patient characteristics and outcomes in diffuse large B-cell lymphoma (DLBCL) before and after the approval of CAR-T therapies. https://lnkd.in/gxukCF88 #DLBCL #Lymphoma #RWD #ASH24

ICYMI: Ontada's recent partnership with Microsoft enabled us to accelerate the analysis of and generate insights for 150 million unstructured oncology documents. Insights from these types of real-world data are key to unlocking breakthroughs in precision oncology. #RWD #AI #PrecisionOncology

Research presented at #ASH24 by Ira Zackon, MD, showed a promising initial uptake of bispecific antibodies for multiple myeloma, especially for Black patients aligning with disease prevalence. While further data on social determinants of health and insurance status are needed to ensure equitable access to advanced therapies, this initial data is encouraging. Read more in this AJMC - The American Journal of Managed Care article: https://lnkd.in/gkX7wM8F #ASH24 #SDOH #Equity #CommunityOncology #MultipleMyeloma

March is Multiple Myeloma Awareness Month. Ontada is proud to contribute to the body of research around this disease, which in 2024 claimed the lives of about 12,540 people in the U.S., according to the National Cancer Institute. But there is hope: ongoing cancer research has led to better and more treatments for multiple myeloma patients, saving and extending countless lives. Check out some of Ontada's most recent research on multiple myeloma below: ?? Demographics and Mortality of Patients Diagnosed with Multiple Myeloma Treated in the US Community Oncology Setting from 2018 to 2023: Assessing Trends in the Pre-, Peri- and Post-Pandemic Eras ?? https://lnkd.in/gwvV7bNu ?? Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting ?? https://lnkd.in/gEKc7FSk #MultipleMyelomaAwarenessMonth #BloodCancer #Leukemia #RWD #Bispecifics

WATCH: Lisa Herms, PhD, speaks to HealthTree Foundation about our real-world study on the utilization of bispecific antibodies for relapsed/refractory multiple myeloma, highlighting the encouraging rapid uptake in community oncology settings despite operational challenges. #Bispecifics #CommunityOncology #MultipleMyeloma #ASH24

Every data point can make a life-changing difference for cancer patients. Ontada, a McKesson business based in Boston, is using Azure AI Foundry and Azure OpenAI Service to unlock insights from 150 million unstructured oncology documents, delivering more robust data faster, and accelerating treatment development. Faster insights mean faster breakthroughs for those who need them most. ??

The Evolution of Ontada: In 2014, McKesson recognized the need for a transformative approach in oncology care, one that would leverage data and insights to enhance the quality and efficiency of care. This marked the beginning of what would become Ontada. With a focus on community oncology, Ontada was created to develop a connected ecosystem designed to utilize data effectively. The goal was to reduce costs while improving patient outcomes. Check out the carousel below to see our journey from our origins in 2014 to today, and learn more about Ontada on our website: https://lnkd.in/grTPbSiy #Data #CancerCare #CommunityOncology

At Ontada, we have a unique view of community cancer care—one that represents data from more than 2.4 million patients across more than 80 tumor types from The US Oncology Network. And now, through our collaboration with Datavant, more life sciences companies can quickly access our real-world data to drive oncology innovation. Learn more: https://lnkd.in/gfj4TrXh #RWD #Oncology #CancerCare #CancerResearch

READ: In this OncLive article, Dr. Ira Zackon discusses the real-world use of bispecific antibodies for patients with relapsed/refractory multiple myeloma in the community oncology setting—and what the next phase of research will look like. Read the full article: https://lnkd.in/gpadFq5J #Bispecifics #MultipleMyeloma #CommunityOncology #ASH24

TODAY at ASCO GU: Don't miss these three research posters being presented in the West Hall and on demand from 7:10 am - 8:10 am and from 11:30 am - 12:45 pm PT: ???? Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting. ?? Abstract number: 470 ?? Poster board: E3 ??? Cherrishe Brown-Bickerstaff, PhD, MPH, Ontada ???? Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies. ?? Abstract number: 501 ?? Poster board: E34 ???? Real-world analysis of Pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC. ?? Abstract number: 480 ?? Poster board: E13 #ASCOGU #mRCC #RCC #RenalCellCarcinoma #RWD